BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35713757)

  • 1. Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake.
    Ramsey ML; Tomlinson J; Pearlman R; Abushahin L; Aeilts A; Chen HZ; Chen Y; Compton A; Elkhatib R; Geiger L; Hays J; Jeter J; Jin N; Malalur P; Roychowdhury S; Ruple J; Prebish J; Stanich PP; Hampel H
    Fam Cancer; 2023 Jan; 22(1):91-97. PubMed ID: 35713757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma.
    Walker EJ; Carnevale J; Pedley C; Blanco A; Chan S; Collisson EA; Tempero MA; Ko AH
    Fam Cancer; 2019 Apr; 18(2):241-251. PubMed ID: 30267352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer.
    Krepline AN; Geurts JL; Akinola I; Christians KK; Clarke CN; George B; Ritch PS; Khan AH; Hall WA; Erickson BA; Griffin MO; Evans DB; Tsai S
    HPB (Oxford); 2020 Dec; 22(12):1745-1752. PubMed ID: 32354656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening.
    Cremin C; Lee MK; Hong Q; Hoeschen C; Mackenzie A; Dixon K; McCullum M; Nuk J; Kalloger S; Karasinska J; Scudamore C; Kim PTW; Donnellan F; Lam ECS; Lim HJ; Neben CL; Stedden W; Zhou AY; Schaeffer DF; Sun S; Renouf DJ; Schrader KA
    Cancer Med; 2020 Jun; 9(11):4004-4013. PubMed ID: 32255556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer.
    Hamilton JG; Symecko H; Spielman K; Breen K; Mueller R; Catchings A; Trottier M; Salo-Mullen EE; Shah I; Arutyunova A; Batson M; Gebert R; Pundock S; Schofield E; Offit K; Stadler ZK; Cadoo K; Carlo MI; Narayan V; Reiss KA; Robson ME; Domchek SM
    Genet Med; 2021 Nov; 23(11):2105-2113. PubMed ID: 34257420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implication and Influence of Multigene Panel Testing with Genetic Counseling in Korean Patients with BRCA1/2 Mutation-Negative Breast Cancer.
    Park JS; Shin S; Lee YJ; Lee ST; Nam EJ; Han JW; Lee SH; Kim TI; Park HS
    Cancer Res Treat; 2022 Oct; 54(4):1099-1110. PubMed ID: 34793666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Variants in Patients With a Family History of Pancreatic Cancer: Impact of Multigene Panel Testing.
    Zhu H; Welinsky S; Soper ER; Brown KL; Abul-Husn NS; Lucas AL
    Pancreas; 2021 Apr; 50(4):602-606. PubMed ID: 33939675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis.
    Sandoval RL; Leite ACR; Barbalho DM; Assad DX; Barroso R; Polidorio N; Dos Anjos CH; de Miranda AD; Ferreira ACSM; Fernandes GDS; Achatz MI
    PLoS One; 2021; 16(2):e0247363. PubMed ID: 33606809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study.
    Uson PLS; Samadder NJ; Riegert-Johnson D; Boardman L; Borad MJ; Ahn D; Sonbol MB; Faigel DO; Fukami N; Pannala R; Kunze K; Golafshar M; Klint M; Esplin ED; Nussbaum RL; Stewart AK; Bekaii-Saab T
    Clin Transl Gastroenterol; 2021 Oct; 12(10):e00414. PubMed ID: 34620795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing.
    Wang Y; Golesworthy B; Cuggia A; Domecq C; Chaudhury P; Barkun J; Metrakos P; Asselah J; Bouganim N; Gao ZH; Chong G; Foulkes WD; Zogopoulos G
    J Med Genet; 2022 Aug; 59(8):793-800. PubMed ID: 34556502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementing Systematic Genetic Counseling and Multigene Germline Testing for Individuals With Pancreatic Cancer.
    Chittenden A; Haraldsdottir S; Ukaegbu C; Underhill-Blazey M; Gaonkar S; Uno H; Brais LK; Perez K; Wolpin BM; Syngal S; Yurgelun MB
    JCO Oncol Pract; 2021 Feb; 17(2):e236-e247. PubMed ID: 33439686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics.
    Kentwell M; Dow E; Antill Y; Wrede CD; McNally O; Higgs E; Hamilton A; Ananda S; Lindeman GJ; Scott CL
    Gynecol Oncol; 2017 Apr; 145(1):130-136. PubMed ID: 28162234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients.
    Culver JO; Ricker CN; Bonner J; Kidd J; Sturgeon D; Hodan R; Kingham K; Lowstuter K; Chun NM; Lebensohn AP; Rowe-Teeter C; Levonian P; Partynski K; Lara-Otero K; Hong C; Morales Pichardo J; Mills MA; Brown K; Lerman C; Ladabaum U; McDonnell KJ; Ford JM; Gruber SB; Kurian AW; Idos GE
    Cancer; 2021 Apr; 127(8):1275-1285. PubMed ID: 33320347
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Harriman JW; Espinel WF; Vagher J; Gammon A
    JCO Precis Oncol; 2022 Oct; 6():e2100375. PubMed ID: 36201716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Family communication and patient distress after germline genetic testing in individuals with pancreatic ductal adenocarcinoma.
    Peters MLB; Stobie L; Dudley B; Karloski E; Allen K; Speare V; Dolinsky JS; Tian Y; DeLeonardis K; Krejdovsky J; Button A; Lim C; Borazanci E; Brand R; Tung N
    Cancer; 2019 Jul; 125(14):2488-2496. PubMed ID: 30980401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic medicine in companion diagnostics of germline BRCA testing of Japanese pancreatic cancer patients.
    Matsubayashi H; Todaka A; Kawakami T; Hamauchi S; Yokota T; Higashigawa S; Kiyozumi Y; Harada R; Kado N; Nishimura S; Ishiwatari H; Sato J; Niiya F; Ono H; Sugiura T; Sasaki K; Yasui H; Yamazaki K
    J Hum Genet; 2023 Feb; 68(2):81-86. PubMed ID: 36482120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients.
    Sabol RA; Ledet EM; Jaeger E; Hatton W; Moses M; Lankford A; Zaheria A; Barata P; Layton JL; Lewis BE; Sartor O
    Prostate; 2021 May; 81(7):427-432. PubMed ID: 33760238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Multigene Testing for Prostate Cancer.
    Berro T; Barrett E; AlDubayan SH
    Urol Clin North Am; 2021 Aug; 48(3):297-309. PubMed ID: 34210486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake.
    Golan T; Casolino R; Biankin AV; Hammel P; Whitaker KD; Hall MJ; Riegert-Johnson DL
    Ther Adv Med Oncol; 2023; 15():17588359231189127. PubMed ID: 37720496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.